

Atty Dkt. No.: STAN-107 DIV
USSN: 09/930,832

In the Claims:

Claims 1-35. (Cancelled)

36. (Currently Amended) A kit for use in preparing a recombinant adenovirus, said kit comprising:

- (a) ~~a first vector comprising~~ an adenoviral genome vector comprising an E gene deletion region and first, second and third restriction endonuclease sites, wherein each of said first, second and third restriction endonuclease sites are: (i) different, (ii) do not occur in the corresponding wild type adenoviral genome and (iii) are located in said E gene deletion region; and
- (b) first, second and third restriction endonucleases that correspond to said first, second and third restriction endonuclease sites.

37. (Currently Amended) The kit according to Claim 36, wherein said first adenoviral genome vector is a plasmid.

38. (Currently Amended) The kit according to Claim 36, wherein said kit further comprises a shuttle vector comprising a multiple cloning site flanked by said first and ~~second~~ third restriction endonuclease sites.

39. (Original) The kit according to Claim 38, wherein said shuttle vector is a plasmid.

40. (Original) The kit according to Claim 36, wherein said kit further comprises a cell that is transcomplementing for any inactivated E genes of said E gene region with said ligation product.

Please enter the following new claims:

Atty Dkt. No.: STAN-107 DIV
USSN: 09/930,832

41. (New) The kit according to Claim 36, wherein said E gene deletion region is characterized by having a deletion of at least one of an E1, E3 and E4 region.
42. (New) The kit according to Claim 36, wherein said first, second and third restriction endonucleases are selected from the group consisting of I-CeuI, PI-SceI and SwaI.
43. (New) The kit according to Claim 36, wherein said adenoviral genome is an AD type 5 genome.
44. (New) A kit for use in preparing a recombinant adenovirus, said kit comprising:
- (a) an adenoviral genome vector comprising an E gene deletion region and first, second and third restriction endonuclease sites, wherein each of said first, second and third restriction endonuclease sites are: (i) different, (ii) do not occur in the corresponding wild type adenoviral genome and (iii) are located in said E gene deletion region;
 - (b) first, second and third restriction endonucleases that correspond to said first, second and third restriction endonuclease sites; and
 - (c) a shuttle vector comprising a multiple cloning site flanked by said first and third restriction endonuclease sites.
45. (New) The kit according to Claim 44, wherein said adenoviral genome vector is a plasmid.
46. (New) The kit according to Claim 44, wherein said shuttle vector is a plasmid.

Atty Dkt. No.: STAN-107 DIV
USSN: 09/930,832

47. (New) The kit according to Claim 44, wherein said kit further comprises a cell that is transcomplementing for any inactivated E genes of said E gene region with said ligation product.

48. (New) The kit according to Claim 44, wherein said E gene deletion region is characterized by having a deletion of at least one of an E1, E3 and E4 region.

49. (New) The kit according to Claim 44, wherein said first, second and third restriction endonucleases are selected from the group consisting of I-CeuI, PI-SceI and SwaI.

50. (New) The kit according to Claim 44, wherein said adenoviral genome is an AD type 5 genome.

51. (New) A kit for use in preparing a recombinant adenovirus, said kit comprising:

(a) an adenoviral genome vector comprising an E gene deletion region and first, second and third restriction endonuclease sites, wherein said first restriction endonuclease site is I-CeuI, said second restriction endonuclease site is SwaI and said third restriction endonuclease site is PI-SceI;

(b) I-CeuI;

(c) PI-SceI;

(d) SwaI; and

(e) a shuttle vector comprising a multiple cloning site flanked by I-CeuI and PI-SceI restriction endonuclease sites.

52. (New) The kit according to Claim 51, wherein said adenoviral genome vector is a plasmid.

Atty Dkt. No.: STAN-107 DIV
USN: 09/930,832

53. (New) The kit according to Claim 51, wherein said shuttle vector is a plasmid.
54. (New) The kit according to Claim 51, wherein said kit further comprises a cell that is transcomplementing for any inactivated E genes of said E gene region with said ligation product.
55. (New) The kit according to Claim 51, wherein said E gene deletion region is characterized by having a deletion of at least one of an E1, E3 and E4 region.
56. (New) The kit according to Claim 51, wherein said adenoviral genome is an AD type 5 genome.